Stefan Neuburger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stefan Neuburger has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
B. Doerken
Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow‐Klinikum, Berlin, Germany
1 shared publicationB. Graf
Institute of Microbiology, Charité University Medicine Berlin, Berlin, Germany
1 shared publicationC. Lutz
Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow‐Klinikum, Berlin, Germany
1 shared publicationG. Massenkeil
Department of Internal Medicine, Hematology and Oncology, Ruhr‐University Bochum, Bochum, Germany
1 shared publication- Georg Maschmeyer
German Society of Hematology and Medical Oncology (DGHO) and Charité University Medicine Berlin, Campus Benjamin Franklin; Department of Hematology, Oncology and Tumor, Charité University Medicine Berlin, Berlin, Germany
1 shared publication I. Tamm
Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow‐Klinikum, Berlin, Germany
1 shared publication
Latest Publications
- 23 July 2008
- Published by Wiley in Transplant Infectious Disease
- Vol. 10 (4) , 290-293
Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation
Fusarium infections are associated with high mortality after allogeneic stem cell transplantation. We report on successful treatment of a disseminated cutaneous Fusarium proliferatum infection using liposomal amphotericin B and terbinafine. In vitro susceptibility tests of antifungal drugs suggest that terbinafine is a potent additional antifungal drug for disseminated cutaneous fusariosis.
- 23 July 2008
- Published by Wiley in Transplant Infectious Disease
- Vol. 10 (4) , 290-293
Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation
Fusarium infections are associated with high mortality after allogeneic stem cell transplantation. We report on successful treatment of a disseminated cutaneous Fusarium proliferatum infection using liposomal amphotericin B and terbinafine. In vitro susceptibility tests of antifungal drugs suggest that terbinafine is a potent additional antifungal drug for disseminated cutaneous fusariosis.
- 11 March 2006
- Published by Springer Nature in Annals of Hematology
- Vol. 85 (6) , 345-356
Update on management of infections in cancer and stem cell transplant patients
Infections are the most important causes of morbidity and mortality in patients with aggressive malignancies and those undergoing allogeneic stem cell transplantation. The introduction of new therapeutic approaches including the use of nucleoside analogs and of monoclonal antibodies to CD20 and CD52 and the increased use of matched unrelated stem cell donors has resulted in new challenges with regard to systemic viral and fungal infections. In patients with bacterial infections, emergence of resistance to formerly widely used antibiotics as well as a shift of causative pathogens towards a predominance of multi-resistant gram-positive cocci has to be taken into consideration. In high-risk neutropenic patients with fever of unknown origin, prompt empiric monotherapy with piperacillin–tazobactam, cefepime, ceftazidime, or a carbapenem is mandatory. In patients with lung infiltrates, early preemptive intervention with an antifungal active against aspergilli is recommended, whereas in patients with catheter-related, skin or soft tissue infections, preemptive addition of a glycopeptide shows a high response rate. The prompt preemptive use of ganciclovir or foscarnet in allogeneic stem cell transplant recipients can reliably be guided by serial monitoring of cytomegalovirus antigen and polymerase chain reaction monitoring.
- 11 March 2006
- Published by Springer Nature in Annals of Hematology
- Vol. 85 (6) , 345-356
Update on management of infections in cancer and stem cell transplant patients
Infections are the most important causes of morbidity and mortality in patients with aggressive malignancies and those undergoing allogeneic stem cell transplantation. The introduction of new therapeutic approaches including the use of nucleoside analogs and of monoclonal antibodies to CD20 and CD52 and the increased use of matched unrelated stem cell donors has resulted in new challenges with regard to systemic viral and fungal infections. In patients with bacterial infections, emergence of resistance to formerly widely used antibiotics as well as a shift of causative pathogens towards a predominance of multi-resistant gram-positive cocci has to be taken into consideration. In high-risk neutropenic patients with fever of unknown origin, prompt empiric monotherapy with piperacillin–tazobactam, cefepime, ceftazidime, or a carbapenem is mandatory. In patients with lung infiltrates, early preemptive intervention with an antifungal active against aspergilli is recommended, whereas in patients with catheter-related, skin or soft tissue infections, preemptive addition of a glycopeptide shows a high response rate. The prompt preemptive use of ganciclovir or foscarnet in allogeneic stem cell transplant recipients can reliably be guided by serial monitoring of cytomegalovirus antigen and polymerase chain reaction monitoring.